COMMUNIQUÉS West-GlobeNewswire

Nika Pharmaceuticals, Inc. (NIKA) Signed a Consultancy Agreement with MD Global Partners LLC
06/03/2026
HENDERSON, Nev., March 06, 2026 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA ) announces that it has signed a consultancy agreement with MD Global Partners LLC, a leading Manhattan-based investment bank. [...]
SleepZee Anti-Snoring Mouthpiece Consumer Report: 2026 Analysis of Mandibular Advancement Device Research, Snoring Reduction Claims, and What Buyers Should Verify
06/03/2026
A 2026 informational consumer research report examining SleepZee anti-snoring mouthpiece mandibular advancement claims, boil-and-bite snoring mouth guard effectiveness research, company Terms of Service disclosures, [...]
Holland Bloorview Kids Rehabilitation Hospital launches its 10th annual Capes for Kids fundraiser
06/03/2026
Calling all fundraisers to don their capes from March 6-13 to support children with disabilities Toronto, March 06, 2026 (GLOBE NEWSWIRE) -- Holland Bloorview Kids Rehabilitation Hospital (Holland Bloorview) kicks off [...]
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
06/03/2026
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS mutant preclinical [...]
Transforming Healthcare Ltd Founder Dr. Pietro Emanuele Garbelli Wins BREW Readers' Book of the Month for 'The Doctor's Future'
06/03/2026
Transforming Healthcare Ltd founder recognised by BREW and profiled by The World’s Best on accountable AI, robotics, and the future of medicine London, GREATER LONDON, March 06, 2026 (GLOBE NEWSWIRE) -- London, UK — 6 [...]
Progyny, Inc. Executives to Participate in Upcoming Investor Conferences
06/03/2026
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that several members of its leadership team will participate in [...]
Standard Dental Labs Inc.: Investor Education Series — Part 3
06/03/2026
Capital to Catalysts: Turning a Public Listing into a Deal Engine ORLANDO, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Standard Dental Labs Inc. (OTCQB: TUTH) today released Part 3 of its Investor Education Series, [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
06/03/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 6 March 2026 at 16.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
06/03/2026
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms Gazyva/Gazyvaro has the potential to [...]
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
06/03/2026
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that [...]
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
06/03/2026
Short Term Tranche Warrants Potentially Raise $10.4 Million within 12 months of Closing SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a [...]
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio
06/03/2026
Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs Transaction represents total equity value of [...]
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
06/03/2026
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced [...]
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
06/03/2026
Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹ Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as well as all other [...]
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
06/03/2026
CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing [...]
Catheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at ISLAA 2026
06/03/2026
FORT MILL, S.C., March 06, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that its LockeT suture [...]
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
06/03/2026
Extends Company Cash Runway into Mid-2028 Financing Expected to Fund Completion of Phase 2 Ovarian Cancer Trial Financing Supports Acceleration Toward Pivotal Trial and Commercialization Financing Structured as Non- [...]
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026
BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today [...]
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
06/03/2026
Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation Rezatapopt granted Orphan [...]

Pages